JP Morgan Chase’s AC Immune ACIU Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $19.6K | Sell |
7,640
-1,081
| -12% | -$3.36K | ﹤0.01% | 6549 |
|
|
2025
Q4 | $27.4K | Buy |
8,721
+1,462
| +20% | +$4.61K | ﹤0.01% | 6433 |
|
|
2025
Q3 | $21K | Buy |
7,259
+1,149
| +19% | +$2.6K | ﹤0.01% | 6462 |
|
|
2025
Q2 | $12.4K | Sell |
6,110
-997
| -14% | -$1.73K | ﹤0.01% | 6272 |
|
|
2025
Q1 | $13.3K | Sell |
7,107
-1,317
| -16% | -$3.32K | ﹤0.01% | 6244 |
|
|
2024
Q4 | $22.7K | Sell |
8,424
-2,272
| -21% | -$7.1K | ﹤0.01% | 6227 |
|
|
2024
Q3 | $40.4K | Sell |
10,696
-656
| -6% | -$2.29K | ﹤0.01% | 6054 |
|
|
2024
Q2 | $45.3K | Sell |
11,352
-10,763
| -49% | -$35.6K | ﹤0.01% | 5899 |
|
|
2024
Q1 | $65.5K | Buy |
22,115
+17,837
| +417% | +$63.9K | ﹤0.01% | 5839 |
|
|
2023
Q4 | $21.4K | Buy |
4,278
+3,078
| +257% | +$9.89K | ﹤0.01% | 6236 |
|
|
2023
Q3 | $3.42K | Sell |
1,200
-1,532
| -56% | -$4.66K | ﹤0.01% | 6437 |
|
|
2023
Q2 | $8.07K | Hold |
2,732
| – | – | ﹤0.01% | 6097 |
|
|
2023
Q1 | $6K | Hold |
2,732
| – | – | ﹤0.01% | 6205 |
|
|
2022
Q4 | $6K | Sell |
2,732
-2,539
| -48% | -$6.54K | ﹤0.01% | 6114 |
|
|
2022
Q3 | $17K | Buy |
5,271
+1,759
| +50% | +$5.54K | ﹤0.01% | 5844 |
|
|
2022
Q2 | $13K | Sell |
3,512
-5,918
| -63% | -$20.2K | ﹤0.01% | 5980 |
|
|
2022
Q1 | $38K | Buy |
9,430
+2,398
| +34% | +$10.4K | ﹤0.01% | 5892 |
|
|
2021
Q4 | $35K | Sell |
7,032
-9,099
| -56% | -$52.9K | ﹤0.01% | 6063 |
|
|
2021
Q3 | $109K | Buy |
16,131
+12,690
| +369% | +$90.8K | ﹤0.01% | 5524 |
|
|
2021
Q2 | $27K | Buy |
3,441
+3,408
| +10,327% | +$23.6K | ﹤0.01% | 5875 |
|
|
2021
Q1 | $0 | Hold |
33
| – | – | ﹤0.01% | 6013 |
|
|
2020
Q4 | $0 | Buy |
+33
| New | +$168 | ﹤0.01% | 5587 |
|
|
2020
Q1 | – | Sell |
-5,059
| Closed | -$43K | – | 5243 |
|
|
2019
Q4 | $43K | Buy |
+5,059
| New | +$33.7K | ﹤0.01% | 5171 |
|
|
2019
Q3 | – | Sell |
-18,162
| Closed | -$99K | – | 5686 |
|
|
2019
Q2 | $99K | Buy |
18,162
+3,113
| +21% | +$15.9K | ﹤0.01% | 4941 |
|
|
2019
Q1 | $76K | Buy |
+15,049
| New | +$95.7K | ﹤0.01% | 4976 |
|
|
2018
Q4 | – | Sell |
-17,803
| Closed | -$142K | – | 5658 |
|
|
2018
Q3 | $142K | Buy |
+17,803
| New | +$179K | ﹤0.01% | 4819 |
|
|
2017
Q2 | – | Sell |
-1,136
| Closed | -$12K | – | 4924 |
|
|
2017
Q1 | $12K | Buy |
+1,136
| New | +$13.9K | ﹤0.01% | 4779 |
|
Other funds holding ACIU
BI
JP Morgan Chase's ACIU Position: Q1 2026 in Review
JP Morgan Chase reduced its AC Immune (ACIU) stake by 12% in Q1 2026, selling an estimated $3.36K and leaving 7,640 shares worth $19.6K. The position accounts for ﹤0.01% of the portfolio, ranked #6549.
JP Morgan Chase first reported a position in ACIU in Q1 2017 and has held it in 27 quarters since. The position peaked at $142K in Q3 2018. 46 funds tracked by Wall St. Rank hold ACIU as of Q1 2026.
- JP Morgan Chase held 7,640 shares of AC Immune worth $19.6K as of Q1 2026.
- JP Morgan Chase sold 1,081 AC Immune shares in Q1 2026, an estimated $3.36K.
- AC Immune made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #6549 holding.
- JP Morgan Chase first reported a position in AC Immune in Q1 2017 and has held it in 27 quarters since.
- JP Morgan Chase's AC Immune position peaked at $142K in Q3 2018.
- 46 funds tracked by Wall St. Rank held AC Immune as of Q1 2026.
Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.